Eagle Pharmacy, Inc., Hoover, AL

Is Eagle Pharmacy, Inc. registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels its entry 503B.

Does Eagle Pharmacy, Inc. hold a Alabama pharmacy license?

State board of pharmacy records for Alabama are not checked: the Board of Pharmacy sends its license roster only by email, after the requester agrees to terms that limit how the data may be used, and its license verification is an interactive search. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0003027 for EAGLE PHARMACY INC, HOOVER, AL, status INACTIVE (EXPIRED MORE THAN 3 YEARS - MUST REAPPLY), as of Nov 15, 2026.

Has Eagle Pharmacy, Inc. had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 untitled letter (May 17, 2022) and 1 FMD-145 letter (Aug 25, 2025) for Eagle Pharmacy, Inc. State board of pharmacy records for Alabama are not checked: the Board of Pharmacy sends its license roster only by email, after the requester agrees to terms that limit how the data may be used, and its license verification is an interactive search.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Eagle Pharmacy, Inc.
Location
Hoover, AL
Type as FDA labels it
503B
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
2
Warning letters on FDA’s actions page
0
Latest action on that page
Aug 25, 2025
FDA Data Dashboard inspections
No matching site found
Form 483 text on this page
1 Form 483, 6 observations
State board records
Not checked

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Eagle Pharmacy, Inc., a 503B facility, with 4 dated actions.

Document
Aug 25, 2025FMD-145 letterFMD-145 Letter Issued 08/25/2025Not linked by FDA
Feb 27, 2025Form 483483 Issued 02/27/2025FDA copy (archived)
May 17, 2022Untitled letterUntitled Letter Issued 05/17/2022FDA copy (archived)
Aug 12, 2021Form 483483 Issued 08/12/2021FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

No inspected site under this exact name and city was found in the FDA Data Dashboard on Nov 15, 2026, searching 12,593 US sites with a drug inspection ending Oct 1, 2008 to Oct 23, 2026. FDA may list the site under another legal name, so this is not a finding that it was never inspected.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 6 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Jul 26, 2021 to Aug 12, 2021: 6 observations

Firm on the cover
Eagle Pharmacy, Inc., 2200 Riverchase Ctr Ste 675, Hoover, AL 35244 -2918
FEI number
3011688532
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
404 BNA Dr., Bldg 200, Ste. 500 Nashville, TN 37217-2597
Matched to this page by
firm name, city and state on the cover; linked from actions page
FDA document
Read the full 483 (Internet Archive copy FDA links)

Observation 1

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically,

1. Environmental monitoring surface sampling conducted in the vial filling room (IS0-5) is not taken in the most critical areas where aseptic manipulations occur. According to the Lead Quality Technician, surface samples are collected on the outer most areas of the LAFW (IS0-5); however, according to the Lead Compounding Technician, aseptic manipulations are performed in the center of the LAFW (IS0-5).

2. Your firm's <Redacted B4> particle counting probe is not placed in an orientation demonstrated to obtain a meaningful sample to monitor non-viable particles during production of your firm's non-dedicated vial filling machine (IS0-5), located in your firm's vial filling machine (IS0-5). According to your firm's Lead Quality Technician, who conducts routine environmental monitoring sampling, the <Redacted B4> particle counting probe is located greater than <Redacted B4> from the most critical area, where the greatest potential risk and highest exposure to the sterilized product occurs.

Observation 2

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room to produce aseptic conditions.

Specifically,

On 7/27/2021, a <Redacted B4> bin was observed being transferred from the ISO-7 classified area lab into the ISO-5 classified area <Redacted B4> room via <Redacted B4> during the production of Triamcholone, Lot <Redacted B4>, without being sanitized.

Observation 3

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic and sterilization process.

Specifically,

1. During our review of the smoke study conducted in June 2020, by your firm's 3rd party contractor,

a. We observed turbulence within the ISO-5 classified area of your firm's <Redacted B4> vial filling machine. The turbulence is observed at your most critical area of production <Redacted B4> during routine interventions. For example, but not limited to, at approximately: The vial filling machine is used to <Redacted B4> drug products at your firm.

___ __ _ We observed turbulence within the ISO-5 classified area of your firm's <Redacted B4> vial filling machine. The turbulence is observed at your most critical area of production <Redacted B4> during routine interventions. For example, but not limited to, at approximately: The vial filling machine is used to <Redacted B4> drug products at your firm.

2. ...

Read the full 483 (Internet Archive copy FDA links)

Observation 4

Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.

Specifically,

1. The document used to capture your firm's personnel and environmental monitoring results is pre-populated with CFU counts of <Redacted B4>. According to your firm's Lead Quality Technician, they do not contemporaneously document their review of personnel and environmental monitoring plates.

2. Your suspension products (Betamethasone, Dexamethasone, Methylprednisolone, Triamcinolone) do not include a specification for particle size.

Observation 5

Batch production and control records do not include complete information relating to the production and control of each batch.

Specifically,

Your firm's media fills did not conduct media fill under worst-case, most challenging conditions. For example• · , but not limited to, prior to this FDA inspection, planned/unplanned interventions were not capture on your firm's batch records. On 08/02/2021 , during the media fill, lot <Redacted B4>, at least interventions were observed.

In addition, on 07/27/2021 during the manufacture of Triamcinolone 50 mg lot <Redacted B4>, at least <Redacted B4> interventions <Redacted B4> were observed during a <Redacted B4> time period. These interventions were not documented on your firm's batch records.

Observation 6

Deviations from written specifications, sampling plans and test procedures are not recorded.

Specifically,

Your firm' s Quality Unit failed to initiate investigations when you deviated from your stability protocols by placing <Redacted B4> instead of <Redacted B4> on stability, missing pre-established time points for testing and testing outside of the protocol. Your Quality Control Manager acknowledged that she should have initiated a deviation investigation. Your firm does not have a quality agreement with the laboratory who conducted your stability testing.

Linked 483s whose text is not shown

State board of pharmacy records

State board of pharmacy records for Alabama are not checked: the Board of Pharmacy sends its license roster only by email, after the requester agrees to terms that limit how the data may be used, and its license verification is an interactive search.

Nonresident licenses in other states

These boards list a nonresident license whose record names this pharmacy’s own name, city and state.

Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).

LicenseType as the board gives itName on the board recordLocationStatus
PCN.0003027NONRESIDENT PHARMACYEAGLE PHARMACY INCHOOVER, ALINACTIVE (EXPIRED MORE THAN 3 YEARS - MUST REAPPLY)

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.